

**Procter & Gamble - I.P. Division****IMPORTANT CONFIDENTIALITY NOTICE**

The documents accompanying this telecopy transmission contain confidential information belonging to the sender which is legally protected. The information is intended only for the use of the individual or entity named below. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopied information is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone (collect) to arrange for return of the telecopied document to us.

**FACSIMILE TRANSMITTAL SHEET AND  
CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8****FAX RECEIVED****JUL 09 2002****GROUP 1600****TO: Examiner A E Pulliam - United States Patent and Trademark Office**

Fax No. (703) 305-3592

Phone No. (703) 308-4710

**OFFICIAL**

*I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on July 8, 2002, to the above-identified facsimile number.*

Andrea L. Winslow (Signature)

**FROM: (Typed or printed name of person signing Certificate) Andrea L. Winslow**

Fax No. (513) 622-3300

Phone No. (513) 622-1822

Listed below are the item(s) being submitted with  
this Certificate of Transmission:

Number of Pages Including this Page: 7

1) Response to Office Action dated 03/08/2002

2) Fee Transmittal Sheet

3)

4)

5)

Inventor(s): Douglas Joseph Dobrozsi

S.N.: 09/361,542

Filed: 07/27/1999

Case: 7247M

Comments:

**FEE TRANSMITTAL  
for FY 2002**

Patent fees are subject to annual revision.

Complete if Known

**FAX RECEIVED**

Application Number 09/361,542

Confirmation Number 5652

Filing Date July 27, 1999

First Named Inventor DOUGLAS JOSEPH DOBKROZSI

Examiner Name A.E. Pulliam

Group/Art Unit 1615

Attorney Docket No. 7247M

TOTAL AMOUNT OF PAYMENT (\$110.00)

**OFFICIAL****METHOD OF PAYMENT (check one)****FEE CALCULATION (continued)**

- 1.
- ☒
- The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number 16-2480

Deposit Account Name The Procter &amp; Gamble Company

- ☒
- Charge Any Additional Fee Required Under status, 37 C.F.R. §§1.16 and 1.17

**FEE CALCULATION****1. BASIC FILING FEE - Large Entity**

Code (S)	Fee Description	Fee Paid
101 740	Utility filing fee	<input type="checkbox"/>
106 330	Design filing fee	<input type="checkbox"/>
108 740	Reissue filing fee	<input type="checkbox"/>
114 160	Provisional filing fee	<input type="checkbox"/>

SUBTOTAL (1) (\$0)

**2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE - Large Entity**

Total Claims	Extra Claims	Fee from Below	Fee Paid
<input type="checkbox"/> - 20** =	<input type="checkbox"/> x	<input type="checkbox"/>	= <input type="checkbox"/>

Independent Claims ☐ - 3\*\* = ☐ x ☐ = ☐Multiple Dependent ☐ - ☐ = ☐

08/01/2002 - Information reviewed and approved if correct. Fee Reissues, see below

01 FC:115c (S) Fee 110.00

Code (S)	Fee Description	Fee Paid
103 18	Claims in excess of 20	<input type="checkbox"/>
102 84	Independent claims in excess of 3	<input type="checkbox"/>
104 280	Multiple dependent claim, if not paid	<input type="checkbox"/>
109 84	**Reissue independent claims over original patent	<input type="checkbox"/>
110 18	**Reissue claims in excess of 20 & over original patent	<input type="checkbox"/>

SUBTOTAL (2) (\$0)

**3. ADDITIONAL FEES**

Code (S)	Fee Description	Fee Paid
105 130	Surcharge-late filing fee or oath	<input type="checkbox"/>
127 50	Surcharge-late provisional filing fee or cover sheet	<input type="checkbox"/>
139 130	Non-English specification	<input type="checkbox"/>
147 2,520	For filing a request for <i>ex parte</i> reexamination	<input type="checkbox"/>
112 920*	Requesting publication of SIR prior to Examiner's action	<input type="checkbox"/>
113 1,840*	Requesting publication of SIR after Examiner's action	<input type="checkbox"/>
115 110	Extension for reply within 1 <sup>st</sup> month	<input checked="" type="checkbox"/>
116 400	Extension for reply within 2 <sup>nd</sup> month	<input type="checkbox"/>
117 920	Extension for reply within 3 <sup>rd</sup> month	<input type="checkbox"/>
118 1,440	Extension for reply within 4 <sup>th</sup> month	<input type="checkbox"/>
128 1,960	Extension for reply within 5 <sup>th</sup> month	<input type="checkbox"/>
119 320	Notice of Appeal	<input type="checkbox"/>
120 320	Filing a brief in support of an appeal	<input type="checkbox"/>
121 280	Request for oral hearing	<input type="checkbox"/>
138 1,510	Petition to institute a public use proceeding	<input type="checkbox"/>
140 110	Petition to revive - unavoidable	<input type="checkbox"/>
141 1,280	Petition to revive - unintentional	<input type="checkbox"/>
142 1,280	Utility issue fee (or reissue)	<input type="checkbox"/>
143 460	Design issue fee	<input type="checkbox"/>
122 130	Petitions to the Commissioner	<input type="checkbox"/>
123 50	Petitions related to provisional applications (37 C.F.R. 1.17(q))	<input type="checkbox"/>
126 180	Submission of Information Disclosure Statement	<input type="checkbox"/>
146 740	Filing a submission after final rejection (37 CFR § 1.129(a))	<input type="checkbox"/>
149 740	For each additional invention to be examined (37 CFR § 1.129(b))	<input type="checkbox"/>
179 740	Request for Continued Examination (RCE)	<input type="checkbox"/>
169 900	Request for expedited examination of a design application	<input type="checkbox"/>
091 1280	Acceptance of unintentionally delayed claim for priority under 35 U.S.C. 119, 120, 121, or 365 (a) or (c)	<input type="checkbox"/>

Other fee (specify) \_\_\_\_\_

Other fee (specify) \_\_\_\_\_

\* Reduced by Basic Filing Fee Paid SUBTOTAL(3) (\$1920)

**SUBMITTED BY****Complete (if applicable)**

Name (Print/Type)	Andrea L. Winslow	Registration No. (Attorney/Agent)	48,586	Telephone	(513) 622-1822
Signature	<i>Andrea L. Winslow</i>			Date	July 8, 2002

WARNING: Information on this form may become public. Credit Card information should not be included on this form. Provide credit card information and authorization on PTO-3013a.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

I hereby certify that this correspondence is being submitted via  
facsimile to: Assistant Commissioner For Patents, Washington,  
D.C. 20231 on July 8, 2002

Andrea L. Winslow 48,516  
Name of Attorney Registration No.  
*Andrea L. Winslow*  
Signature of Attorney

P&amp;G Case 7247M

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :  
DOUGLAS J. DOBROZSI :  
Serial No. 09/361,542 : Group Art Unit 1615  
Filed July 27, 1999 : Examiner A. Pulliam  
For: ORAL LIQUID MUCOADHESIVE COMPOSITIONS

AMENDMENT UNDER 37 C.F.R. §1.111

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the Office Action of March 8, 2002, please enter the following amendment and consider the following remarks in support of patentability. The Commissioner is authorized to charge any necessary fees to Deposit Account No. 16-2480. Applicant believes that a one (1) month extension of time is necessary and respectfully requests that the Commissioner grants the extension.

IN THE CLAIMS

Please cancel Claim 31 and 33-35 and add newly presented Claims 36-41.

E1  
36  
Claim 36 (new). A method of administering an active agent to one or more of the esophagus, stomach and small intestine by swallowing a safe and effective amount of a mucoretentive composition comprising from about 2% to about 50%, by weight of the composition, of colloidal particles of silica and a safe and effective amount of a pharmaceutical active selected from the group consisting of gastrointestinal agents, analgesics, decongestants, expectorants, antitussives, antihistamines, bronchodilators, topical anesthetics, sensory agents and mixtures thereof.